NAMS: NewAmsterdam Pharma Company N.V

NAMS新闻

• 13:32 RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42
• 12:03 NewAmsterdam Pharma Announces Dosing Of First Participant In SPINOZA, Phase 2b Clinical Trial Evaluating Obicetrapib In Individuals With Preclinical Alzheimer’s Disease
• 12:03 NewAmsterdam Pharma宣布SPINOZA二期b临床试验首位受试者已开始给药，该试验旨在评估obicetrapib在临床前阿尔茨海默病患者中的作用
• 13:03 新阿姆斯特丹制药获得欧洲委员会批准Ubeslo和Evlarco治疗原发性高胆固醇血症的营销授权
• 13:03 NewAmsterdam Pharma Receives Marketing Authorization From European Commission For Ubeslo, Evlarco To Treat Primary Hypercholesterolaemia
• 12:47 Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
• 15:16 Stock Market Falls On Soaring Oil Prices, Yields, But Finishes Strong; CPI Inflation, Apple, Oracle, Meta In Focus: Weekly Review
• 13:56 How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma
• 12:01 Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Baidu
• 08:15 Why the Dow is being dragged down by a Swiss company’s bad news
• 03:14 NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
• 13:55 NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
• 03:58 NewAmsterdam Pharma Stock: Obicetrapib More Than Another LDL-Lowering Pill (NASDAQ:NAMS)
• 07:10 Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio – Q1 2026 Update
• 04:52 NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript